CLASS II ONGOING Drug recall · Reported 11 Nov 2026 · FDA Enforcement Report
Ciprofloxacin Tablets, USP, 500 mg recalled by Hikma Pharmaceuticals USA
Hikma Pharmaceuticals USA is recalling Ciprofloxacin Tablets, USP, 500 mg, distributed nationwide in the US. The recall was initiated on 20 Oct 2026 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0165-2027
- FDA event ID
- 100142
- Recalling firm
- Hikma Pharmaceuticals USA, Columbus, OH
- Brand
- Ciprofloxacin
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- 20 Oct 2026
- FDA classified
- 3 Nov 2026
- Reported
- 11 Nov 2026
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Nitrosamine Impurity
- Drug class
- Antibiotics
Timeline
| 20 Oct 2026 | Recall initiated by company | |
| 3 Nov 2026 | Classified by FDA | +14 days |
| 11 Nov 2026 | Published in enforcement report | +8 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.
Product as listed by the FDA
Ciprofloxacin Tablets, USP, 500 mg, 100-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9928-01
Where it was distributed
US Nationwide
Questions about this recall
Why was it recalled?
CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
Which lots are affected?
Lot# CB496A; Exp. 12/31/2026 Lot# CB497A; Exp. 12/31/2026 Lot# CB498A; Exp. 12/31/2026
Where was it sold?
US Nationwide
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 17 Nov 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other products in this recall event
1 other product · FDA event 100142This product is part of a recall event; the main page for the event is Ciprofloxacin Tablets, USP, 750 mg recalled by Hikma Pharmaceuticals USA.
| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| CLASS II | Ciprofloxacin Tablets, USP, 750 mg recalled by Hikma Pharmaceuticals USACiprofloxacin | Hikma Pharmaceuticals USA | Nitrosamine Impurity | Nationwide |
More recalls from Hikma Pharmaceuticals USA
All 23| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Ciprofloxacin Tablets, USP, 750 mg recalled by Hikma Pharmaceuticals USACiprofloxacin | Hikma Pharmaceuticals USA | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Abirtega (abiraterone acetate) USP, 250 mg recalledAbirtega | Hikma Pharmaceuticals USA | Other | Nationwide |
| Drug | CLASS II | Ramipril Capsules USP, 10 mg recalled by Hikma Pharmaceuticals USARamipril | Hikma Pharmaceuticals USA | Potency & Assay | Nationwide |
| Drug | CLASS II | Alendronate Sodium Oral Solution, 70 mg recalledAlendronate Sodium | Hikma Pharmaceuticals USA | Potency & Assay | Nationwide |
| Drug | CLASS II | Lorazepam Injection, USP, 2 mg/mL, 25 x vials/carton recalledLorazepam | Hikma Pharmaceuticals USA | Potency & Assay | Nationwide |
Other Ciprofloxacin recalls
All 21| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Ciprofloxacin Tablets, USP, 750 mg recalled by Hikma Pharmaceuticals USACiprofloxacin | Hikma Pharmaceuticals USA | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension recalledCiprofloxacin And Dexamethasone | Sandoz | Temperature Abuse | CA |
| Drug | CLASS II | Ciprofloxacin Ophthalmic Solution USP, 0.3% as base, package recalledCiprofloxacin | FDC | Packaging Defects | Nationwide |
| Drug | CLASS II | Ciprofloxacin Ophthalmic Solution USP, 0.3% as base recalled by FDCCiprofloxacin | FDC | Packaging Defects | Nationwide |
| Drug | CLASS II | Ciprofloxacin ophthalmic solution USP, 0.3% as base recalled by FDCCiprofloxacin | FDC | Packaging Defects | Nationwide |